VORVor Biopharma Inc.
$19.16-43% 1Y
$19.16
$6.8652 weeks$33.40
Price
-43%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growth fading, the market undecided.
P/En/a
Market value$1.04B
1 year-43%
5 years-94%
Charts
As reported to the SEC, without any scoring.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 7, 2026Resignation of Andrew Levin, M.D., Ph.D. as a Director On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.Director or officer change · Form 8-K
- Jun 8, 2026Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China.Regulation FD disclosure · press release
- Mar 27, 2026On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.